Harold Eugene Brakewood Purchases 5,250 Shares of Immuneering (NASDAQ:IMRX) Stock

Immuneering Corporation (NASDAQ:IMRX) insider Harold Eugene Brakewood purchased 5,250 shares of the business’s stock in a transaction on Friday, January 16th. The stock was purchased at an average cost of $4.76 per share, for a total transaction of $24,990.00. Following the completion of the acquisition, the insider directly owned 11,050 shares of the company’s stock, valued at approximately $52,598. The trade was a 90.52% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Immuneering Trading Up 10.1%

Shares of IMRX opened at $5.34 on Friday. The firm has a market cap of $344.80 million, a PE ratio of -3.00 and a beta of 0.48. Immuneering Corporation has a 12 month low of $1.10 and a 12 month high of $10.08. The stock has a fifty day moving average price of $6.22 and a 200-day moving average price of $5.82.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Wednesday, November 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.01). As a group, research analysts forecast that Immuneering Corporation will post -1.86 EPS for the current year.

Institutional Investors Weigh In On Immuneering

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. purchased a new position in shares of Immuneering during the 3rd quarter valued at about $35,000. Future Financial Wealth Managment LLC acquired a new stake in Immuneering during the third quarter worth about $35,000. Mercer Global Advisors Inc. ADV purchased a new position in Immuneering during the third quarter valued at approximately $70,000. Moors & Cabot Inc. purchased a new position in Immuneering during the third quarter valued at approximately $77,000. Finally, Virtu Financial LLC acquired a new position in Immuneering in the third quarter valued at approximately $98,000. 67.65% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on IMRX shares. Chardan Capital reaffirmed a “buy” rating and issued a $20.00 price target on shares of Immuneering in a report on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a research note on Monday, December 29th. Mizuho set a $12.00 price target on Immuneering in a research report on Wednesday, October 29th. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Immuneering in a report on Tuesday, September 30th. Finally, Oppenheimer raised their price objective on Immuneering from $21.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Immuneering presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.